Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 11/2013

01-10-2013 | Bone and Soft Tissue Sarcomas

Surgical Treatment of Pediatric Desmoid Tumors. A 12-Year, Single-Center Experience

Authors: Miguel A. Soto-Miranda, MD, John A. Sandoval, MD, Bhaskar Rao, MD, Mike Neel, MD, Matt Krasin, MD, Sheri Spunt, MD, Jesse J. Jenkins, MD, Andrew M. Davidoff, MD, Jon P. Ver Halen, MD, FACS

Published in: Annals of Surgical Oncology | Issue 11/2013

Login to get access

Abstract

Background

Pediatric desmoid tumors (PDTs) represent a group of rare, distinct lesions. While sparse, available literature suggests that PDT are particularly aggressive and difficult to control when compared with their adult counterpart.

Methods

A retrospective review identified 39 patients who underwent treatment of PDT at St. Jude Children’s Research Hospital over a 12-year period. Clinicopathologic and treatment characteristics were analyzed to identify predictors of outcome.

Result

A total of 39 patients were treated during the study period, with a total number of 67 resections. Median age was 12.2 years; 49 % of patients were male, and 51 % were female. Median tumor size was 9.8 cm. PDT most commonly arose in the extremities (40 %), thorax (23 %), head and neck (21 %), and trunk (16 %). Also, 18 % of resections had negative margins (R0), 48 % were microscopic positive (R1), and 30 % were macroscopic positive (R2). The 1- and 5-year recurrence-free survival (RFS) was 97.1 and 73.1 %, respectively. Factors associated with worse RFS were patient age >12 years (HR = 5.08, p = 0.038) and tumor size >5 cm (HR = 1.22, p = 0.0597). Margin status did not affect RFS. Selective use of radiation therapy appeared to improve RFS.

Conclusions

Our study suggests that margin status alone at the time of extirpation is not a predictor of ultimate cure or likelihood of recurrence. Many patients received adjuvant therapy, with benefits suggested after analysis. For patients with PDT, surgical extirpation should not come at the expense of functional preservation, as overall survival is excellent.
Literature
1.
Rao BN, Horowitz ME, Parham DM, Etcubanas EE, Fleming ID, Pratt CB, et al. Challenges in the treatment of childhood fibromatosis. Arch Surg. 1987;122:1296–8.PubMedCrossRef
2.
Reitamo JJ, Scheinin TM, Häyry P. The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg. 1986;151:230–7.PubMedCrossRef
3.
Meazza C, Bisogno G, Gronchi A, Fiore M, Cecchetto G, Alaggio R, et al. Aggressive fibromatosis in children and adolescents: the Italian experience. Cancer. 2010;116:233–40.PubMed
4.
Sharma A, Ngan B-Y, Sándor GKB, Campisi P, Forte V. Pediatric aggressive fibromatosis of the head and neck: a 20-year retrospective review. J Pediatr Surg. 2008;43:1596–604.PubMedCrossRef
5.
Kasper B, Ströbel P, Hohenberger P. Desmoid tumors: clinical features and treatment options for advanced disease. Oncologist. 2011;16:682–93.PubMedCrossRef
6.
Posner MC, Shiu MH, Newsome JL, Hajdu SI, Gaynor JJ, Brennan MF. The desmoid tumor. Not a benign disease. Arch Surg. 1989;124:191–6.PubMedCrossRef
7.
Rutenberg MS, Indelicato DJ, Knapik JA, Lagmay JP, Morris C, Zlotecki RA, et al. External-beam radiotherapy for pediatric and young adult desmoid tumors. Pediatr Blood Cancer. 2011;57:435–42.PubMedCrossRef
8.
Bertario L, Russo A, Sala P, Varesco L, Giarola M, Mondini P, et al. Multiple approach to the exploration of genotype–phenotype correlations in familial adenomatous polyposis. J Clin Oncol. 2003;21:1698–707.PubMedCrossRef
9.
10.
Dahn I, Jonsson N, Lundh G. Desmoid tumours. A series of 33 cases. Acta Chir Scand. 1963;126:305–14.PubMed
11.
Casali PG, Blay J-Y. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v98–102.PubMedCrossRef
12.
Lev D, Kotilingam D, Wei C, Ballo MT, Zagars GK, Pisters PWT, et al. Optimizing treatment of desmoid tumors. J Clin Oncol. 2007;25:1785–91.PubMedCrossRef
13.
Lazar AJF, Hajibashi S, Lev D. Desmoid tumor: from surgical extirpation to molecular dissection. Curr Opin Oncol. 2009;21:352–9.PubMedCrossRef
14.
Merchant TE, Nguyen D, Walter AW, Pappo AS, Kun LE, Rao BN. Long-term results with radiation therapy for pediatric desmoid tumors. Int J Radiat Oncol Biol Phys. 2000;47:1267–71.PubMedCrossRef
15.
Faulkner LB, Hajdu SI, Kher U, La Quaglia M, Exelby PR, Heller G, et al. Pediatric desmoid tumor: retrospective analysis of 63 cases. J Clin Oncol. 1995;13:2813–8.PubMed
16.
Oudot C, Orbach D, Minard-Colin V, Michon J, Mary P, Glorion C, et al. Desmoid fibromatosis in pediatric patients: management based on a retrospective analysis of 59 patients and a review of the literature. Sarcoma. 2012;2012:475202 (9 pages). doi:10.​1155/​2012/​475202.
17.
Bonvalot S, Eldweny H, Haddad V, Rimareix F, Missenard G, Oberlin O, et al. Extra-abdominal fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol. 2008;34:462–8.PubMedCrossRef
18.
Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Péchoux C, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16:2587–93.PubMedCrossRef
19.
de Bree E, Keus R, Melissas J, Tsiftsis D, van Coevorden F. Desmoid tumors: need for an individualized approach. Expert Rev Anticancer Ther. 2009;9:525–35.PubMedCrossRef
20.
Raney B, Evans A, Granowetter L, Schnaufer L, Uri A, Littman P. Nonsurgical management of children with recurrent or unresectable fibromatosis. Pediatrics. 1987;79:394–8.PubMed
21.
Salas S, Chibon F, Noguchi T, Terrier P, Ranchere-Vince D, Lagarde P, et al. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer. 2010;49:560–8.PubMed
22.
Lazar AJ, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoids tumors. Am J Pathol. 2008;173:1518–27.PubMedCrossRef
23.
Casali PG, Blay JY. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:198–203.CrossRef
24.
Mullen JT, DeLaney TF, Kobayashi WK, Szymonifka J, Yeap BY, Chen YL, et al. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol. 2012;19:4028–35.PubMedCrossRef
25.
Peng PD, Hyder O, Mavros MN, Turley R, Groeschl R, Firoozmand A, et al. Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol. 2012;19:4036–42.PubMedCrossRef
26.
Skapek SX, Hawk BJ, Hoffer FA, Dahl GV, Granowetter L, Gebhardt MC, et al. Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children. J Clin Oncol. 1998;16:3021–7.PubMed
27.
Bertani E, Chiappa A, Testori A, Mazzarol G, Biffi R, Martella S, et al. Desmoid tumors of the anterior abdominal wall: results from a monocentric surgical experience and review of the literature. Ann Surg Oncol. 2009;16:1642–9.PubMedCrossRef
28.
Abbas AE, Deschamps C, Cassivi SD, Nichols III FC, Allen MS, Schleck CD, et al. Chest-wall desmoid tumors: results of surgical intervention. Ann Thorac Surg. 2004;78:1219–23.PubMedCrossRef
29.
Gronchi A, Casali PG, Mariani L, Lo Vullo S, Colecchia M, Lozza L, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol. 2003;21:1390–7.PubMedCrossRef
30.
Gronchi A, Raut CP. Optimal approach to sporadic desmoid tumors: from radical surgery to observation. Time for a consensus? Ann Surg Oncol. 2012;19:3995–7.PubMedCrossRef
31.
Spear MA, Jennings LC, Mankin HJ, Spiro IJ, Springfield DS, Gebhardt MC, et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys. 1998;40;637–45.PubMedCrossRef
32.
Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999;17:158–67.PubMed
33.
Ballo MT, Zagars GK, Pollack A. Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys. 1998;42:1007–14.PubMedCrossRef
34.
Kamath SS, Parsons JT, Marcus RB, Zlotecki RA, Scarborough MT. Radiotherapy for local control of aggressive fibromatosis. Int J Radiat Oncol Biol Phys. 1996;36:325–8.PubMedCrossRef
35.
Skapek SX, Ferguson WS, Granowetter L, Devidas M, Perez-Atayde AR, Dehner LP, et al. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol. 2007;25:501–6.PubMedCrossRef
36.
Skapek SX, Anderson JR, Hill DA, Henry D, Spunt SL, Meyer W, et al. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children’s Oncology Group (COG) Phase II Study. Pediatr Blood Cancer. 2013;60:1108–12.PubMedCrossRef
37.
Gounder MM, Lefkowitz RA, Keohan ML, D’Adamo DR, Hameed M, Antonescu CR, et al. Activity of sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res. 2011;17:4082–90.PubMedCrossRef
Metadata
Title
Surgical Treatment of Pediatric Desmoid Tumors. A 12-Year, Single-Center Experience
Authors
Miguel A. Soto-Miranda, MD
John A. Sandoval, MD
Bhaskar Rao, MD
Mike Neel, MD
Matt Krasin, MD
Sheri Spunt, MD
Jesse J. Jenkins, MD
Andrew M. Davidoff, MD
Jon P. Ver Halen, MD, FACS
Publication date
01-10-2013
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 11/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-3090-7

Other articles of this Issue 11/2013

Annals of Surgical Oncology 11/2013 Go to the issue

Colorectal Cancer

Less Than 12 Nodes in the Surgical Specimen After Total Mesorectal Excision Following Neoadjuvant Chemoradiation: It means more than you think!

Gastrointestinal Oncology

A Systematic Review and Meta-Analysis Comparing Laparoscopic Versus Open Gastric Resections for Gastrointestinal Stromal Tumors of the Stomach

Colorectal Cancer

Lymph Node Assessment: Quality, Not Quantity

Breast Oncology

Profile and Predictors of Long-term Morbidity in Breast Cancer Survivors

Breast Oncology

Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer

Thoracic Oncology

Surgical Prevention of Reflux after Esophagectomy for Cancer